Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (5090)	8/6/1998 3:05:00 PM
From: Peter Singleton	Respond to of 6136

PB, I don't have my notes in front of me, but ISIP has an intiative to patent antisense approaches to a broad number of targets. If I remember correctly, they are taking genes of interest, synthesizing then evaluating antisense oligos, then patenting them. They are doing this to establish antisense rights on targets they don't currently have discovery programs for. It's an automated process, and I think their goal is 2 a week. It's unclear to me how their patent position on the antisense application of these genes will stand up against an a priori awarded patent on the sequence of interest, with "antisense" rights, with no antisense specific work. In this I'm decidedly one of those amateurs weighing in on a subject I'm a little out of my dept on (Rick, I know!) Peter